FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Yun Dai

Research Profile

Chemicals & Drugs

Physiology

Anatomy

Disorders

Procedures

Antineoplastic Combined Chemotherapy Protocols

Co-author Network

Publications

TOP 3
Alae Yaseen; Stefanie Hock; Roberto Rosato; Shuang Chen; Yun Dai; Paul Dent; Steven Grant
Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
Shuang Chen; Yun Dai; Paul Dent; Mandy Garnett; Lora B Kramer; Dustin G Larsen; Jennifer Myers; Robert Z Orlowski; Xin-Yan Pei; Justin D Richey; Daniella M Schwartz; Gary L Simmons; Florence Su; Li Wang; Steven Grant
CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Yong Tang; Yun Dai; Steven Grant; Hossein A Hamed; Andrew Poklepovic; Paul Dent
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Yun Dai (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Alae Yaseen; Stefanie Hock; Roberto Rosato; Shuang Chen; Yun Dai; Paul Dent; Steven Grant
Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
Molecular pharmacology 2012;82(6):1030-41.
2012: Shuang Chen; Yun Dai; Paul Dent; Mandy Garnett; Lora B Kramer; Dustin G Larsen; Jennifer Myers; Robert Z Orlowski; Xin-Yan Pei; Justin D Richey; Daniella M Schwartz; Gary L Simmons; Florence Su; Li Wang; Steven Grant
CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Cancer research 2012;72(16):4225-37.
2012: Yong Tang; Yun Dai; Steven Grant; Hossein A Hamed; Andrew Poklepovic; Paul Dent
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
Molecular pharmacology 2012;82(2):322-32.
2012: Yong Tang; Steven Grant; Yun Dai; Paul Dent
Enhancing CHK1 inhibitor lethality in glioblastoma.
Cancer biology & therapy 2012;13(6):379-88.
2012: Roberto Rosato; Stefanie Hock; Yun Dai; Paul Dent; Steven Grant
LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.
Leukemia research 2012;36(4):491-8.
2012: Steven Grant; Yun Dai
Histone deacetylase inhibitors and rational combination therapies.
Advances in cancer research 2012;116():199-237.
2011: Xin-Yan Pei; Yukie Takabatake; Leena E Youssefian; Lora B Kramer; Jorge A Almenara; Wesley W Bodie; Shuang Chen; Yun Dai; Paul Dent; Jessica Felthousen; Steven Grant
Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.
Blood 2011;118(19):5189-200.
2011: Yun Dai; Paul Dent; Vanessa L Funk; Lora B Kramer; Xin-Yan Pei; Li Wang; Shuang Chen; Steven Grant
Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.
The Journal of biological chemistry 2011;286(39):34036-50.
2011: Qifang Zhang; Masoud Manjili; Kazuya Shimoda; Jamie L Sturgill; Karol Szczepanek; Harry Bear; Shuang Chen; Joanna Cichy; Daniel Conrad; Yun Dai; Marta Derecka; Ana M Gamero; Laura J Graham; Steven Grant; Maciej Kmieciak; Catherine Koebel; Andrew C Larner
The role of Tyk2 in regulation of breast cancer growth.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2011;31(9):671-7.
2011: Clint Mitchell; Yong Tang; Gary Tye; Adly Yacoub; M Danielle Bareford; Nichola Cruickshanks; Yun Dai; Steven Grant; Hossein A Hamed; Nissan Hubbard; Paul Dent
Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
Cancer biology & therapy 2011;12(3):215-28.
2011: Tri Nguyen; Yun Dai; Elisa Attkisson; Lora Kramer; Nicholas Jordan; Nguyen Nguyen; Nikhil Kolluri; Markus Muschen; Steven Grant
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(10):3219-32.
2011: Paul Dent; Yong Tang; Adly Yacoub; Yun Dai; Paul B Fisher; Steven Grant
CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.
Molecular interventions 2011;11(2):133-40.
2011: Yun Dai; Paul Dent; Lora B Kramer; Xin-Yan Pei; Li Wang; Shuang Chen; Steven Grant
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
British journal of haematology 2011;153(2):222-35.
2011: Yun Dai; Shuang Chen; Rena Shah; Xin-Yan Pei; Li Wang; Jorge A Almenara; Lora B Kramer; Paul Dent; Steven Grant
Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
Blood 2011;117(6):1947-57.
2011: Yun Dai; Steven Grant
Methods to study cancer therapeutic drugs that target cell cycle checkpoints.
Methods in molecular biology (Clifton, N.J.) 2011;782():257-304.
2010: Yun Dai; Monica L Guzman; Shuang Chen; Li Wang; Sin-Kei Yeung; Xin-Yan Pei; Paul Dent; Craig T Jordan; Steven Grant
The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells.
British journal of haematology 2010;151(1):70-83.
2010: Yun Dai; Steven Grant
Targeting Chk1 in the replicative stress response.
Cell cycle (Georgetown, Tex.) 2010;9(6):1025.
2010: Yun Dai; Steven Grant
New insights into checkpoint kinase 1 in the DNA damage response signaling network.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(2):376-83.
2009: Shuang Chen; Yun Dai; Xin-Yan Pei; Steven Grant
Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
Molecular and cellular biology 2009;29(23):6149-69.
2009: J Wang; Takefumi Ishii; Wei Zhang; Selcuk Sozer; Yun Dai; J Mascarenhas; V Najfeld; Z J Zhao; Ronald Hoffman; N Wisch; Mingjiang Xu
Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
Leukemia 2009;23(9):1577-86.
2008: Yun Dai; Shuang Chen; Xin-Yan Pei; Jorge A Almenara; Lora B Kramer; Charis A Venditti; Paul Dent; Steven Grant
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.
Blood 2008;112(6):2439-49.
2008: Yun Dai; Shuang Chen; Charis A Venditti; Xin-Yan Pei; Tri K Nguyen; Paul Dent; Steven Grant
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
Blood 2008;112(3):793-804.
2008: Hossein Hamed; William Hawkins; Clint Mitchell; Donna Gilfor; Guo Zhang; Xin-Yan Pei; Yun Dai; Michael P Hagan; John D Roberts; Adly Yacoub; Steven Grant; Paul Dent
Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo.
Molecular cancer therapeutics 2008;7(3):616-29.
2008: Yun Dai; Shuang Chen; Lora B Kramer; Vanessa L Funk; Paul Dent; Steven Grant
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):549-58.
2007: Xin-Yan Pei; Yun Dai; Sarah Tenorio; Jianghua Lu; Hisashi Harada; Paul Dent; Steven Grant
MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
Blood 2007;110(6):2092-101.
2007: Girija Dasmahapatra; Nitin Yerram; Yun Dai; Paul Dent; Steven Grant
Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4280-90.
2007: Yun Dai; Payal Khanna; Shuang Chen; Xin-Yan Pei; Paul Dent; Steven Grant
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
Blood 2007;109(10):4415-23.
2007: Yun Dai; Steven Grant
Targeting multiple arms of the apoptotic regulatory machinery.
Cancer research 2007;67(7):2908-11.
2007: Shuang Chen; Yun Dai; Hisashi Harada; Paul Dent; Steven Grant
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Cancer research 2007;67(2):782-91.
2006: Xin-Yan Pei; Weiqun Li; Yun Dai; Paul Dent; Steven Grant
Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells.
Molecular pharmacology 2006;70(6):1965-73.
2006: Yun Dai; Steven Grant
CDK inhibitor targets: a hit or miss proposition?: cyclin-dependent kinase inhibitors kill tumor cells by downregulation of anti-apoptotic proteins.
Cancer biology & therapy 2006;5(2):171-3.
2006: Yun Dai; Tracy E Hamm; Paul Dent; Steven Grant
Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry.
Cell cycle (Georgetown, Tex.) 2006;5(4):437-46.
2005: William Hawkins; Clint Mitchell; Robert McKinstry; Donna Gilfor; James Starkey; Yun Dai; Kathy Dawson; Viswanathan Ramakrishnan; John D Roberts; Adly Yacoub; Steven Grant; Paul Dent
Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth.
Cancer biology & therapy 2005;4(11):1275-84.
2005: Yun Dai; Mohamed Rahmani; Paul Dent; Steven Grant
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
Molecular and cellular biology 2005;25(13):5429-44.
2005: Xin-Yan Pei; Yun Dai; Mohamed Rahmani; Weiqun Li; Paul Dent; Steven Grant
The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4589-600.
2005: Mohamed Rahmani; Erin Reese; Yun Dai; Cheryl Bauer; Lora B Kramer; Mei Huang; Richard Jove; Paul Dent; Steven Grant
Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
Molecular pharmacology 2005;67(4):1166-76.
2005: Mohamed Rahmani; Erin Reese; Yun Dai; Cheryl Bauer; Shawn G Payne; Paul Dent; Sarah Spiegel; Steven Grant
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Cancer research 2005;65(6):2422-32.
2005: Yun Dai; Mohamed Rahmani; Xin-Yan Pei; Payal Khanna; Song Iy Han; Clint Mitchell; Paul Dent; Steven Grant
Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
Blood 2005;105(4):1706-16.
2004: Xin-Yan Pei; Yun Dai; Steven Grant
The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
Molecular cancer therapeutics 2004;3(12):1513-24.
2004: Roberto R Rosato; Yun Dai; Jorge A Almenara; Sonia C Maggio; Steven Grant
Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Leukemia 2004;18(11):1780-8.
2004: Ning Gao; Yun Dai; Mohamed Rahmani; Paul Dent; Steven Grant
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Molecular pharmacology 2004;66(4):956-63.
2004: Yun Dai; Mohamed Rahmani; Seth J Corey; Paul Dent; Steven Grant
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
The Journal of biological chemistry 2004;279(33):34227-39.
2004: Yun Dai; Mohamed Rahmani; Xin-Yan Pei; Paul Dent; Steven Grant
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Blood 2004;104(2):509-18.
2004: Xin-Yan Pei; Yun Dai; Steven Grant
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3839-52.
2004: Sonia C Maggio; Roberto R Rosato; Lora B Kramer; Yun Dai; Mohamed Rahmani; David S Paik; Ann C Czarnik; Shawn G Payne; Sarah Spiegel; Steven Grant
The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
Cancer research 2004;64(7):2590-600.
2004: Yun Dai; Xin-Yan Pei; Mohamed Rahmani; Daniel H Conrad; Paul Dent; Steven Grant
Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells.
Blood 2004;103(7):2761-70.
2004: Yun Dai; Steven Grant
Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents.
Current oncology reports 2004;6(2):123-30.
2003: Roberto R Rosato; Jorge A Almenara; Yun Dai; Steven Grant
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.
Molecular cancer therapeutics 2003;2(12):1273-84.
2003: Mohamed Rahmani; Chunrong Yu; Yun Dai; Erin Reese; Wesam Ahmed; Paul Dent; Steven Grant
Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
Cancer research 2003;63(23):8420-7.
2003: Yun Dai; Paul Dent; Steven Grant
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL.
Molecular pharmacology 2003;64(6):1402-9.
2003: Yun Dai; Mohamed Rahmani; Steven Grant
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Oncogene 2003;22(46):7108-22.
2003: Xin-Yan Pei; Yun Dai; Steven Grant
The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.
Leukemia 2003;17(10):2036-45.
2003: Yun Dai; Mohamed Rahmani; Steven Grant
An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells.
Cell cycle (Georgetown, Tex.) 2003;2(5):467-72.
2003: Yun Dai; Steven Grant
Cyclin-dependent kinase inhibitors.
Current opinion in pharmacology 2003;3(4):362-70.
2003: Roy H Decker; JAY LEVIN; Lora B Kramer; Yun Dai; Steven Grant
Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[beta-D-arabinofuranosyl]cytosine (ara-C)-induced apoptosis.
Biochemical pharmacology 2003;65(12):1997-2008.
2003: Chunrong Yu; Mohamed Rahmani; Yun Dai; Daniel Conrad; Geoffrey W Krystal; Paul Dent; Steven Grant
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Cancer research 2003;63(8):1822-33.
2002: Chunrong Yu; Yun Dai; Paul Dent; Steven Grant
Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
Cancer biology & therapy 2002;1(6):674-82.
2002: Yun Dai; Terry Landowski; Steven T Rosen; Paul Dent; Steven Grant
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
Blood 2002;100(9):3333-43.
2002: Mohamed Rahmani; Yun Dai; Steven Grant
The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process.
Experimental cell research 2002;277(1):31-47.
2002: Leanne Cartee; Rebecca Smith; Yun Dai; Mohamed Rahmani; Roberto R Rosato; Jorge A Almenara; Paul Dent; Steven Grant
Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways.
Molecular pharmacology 2002;61(6):1313-21.
2002: Robert McKinstry; Liang Qiao; Adly Yacoub; Yun Dai; Roy H Decker; Shawn Holt; Michael P Hagan; Steven Grant; Paul Dent
Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells.
Cancer biology & therapy 2002;1(3):243-53.
2002: Zhiliang Wang; Shujie Wang; Yun Dai; Steven Grant
Bryostatin 1 increases 1-beta-D-arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-x(L).
The Journal of pharmacology and experimental therapeutics 2002;301(2):568-77.
2002: Yun Dai; Paul Dent; Steven Grant
Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A.
Cell cycle (Georgetown, Tex.) 2002;1(2):143-52.
2002: Roy H Decker; Shujie Wang; Yun Dai; Paul Dent; Steven Grant
Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis.
Cancer biology & therapy 2002;1(2):136-44.
2001: Roy H Decker; Yun Dai; Steven Grant
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway.
Cell death and differentiation 2001;8(7):715-24.
2001: Yun Dai; C Yu; V Singh; L Tang; Z Wang; R McInistry; Paul Dent; Steven Grant
Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.
Cancer research 2001;61(13):5106-15.
2001: S Harvey; Roy H Decker; Yun Dai; G Schaefer; L Tang; Lora Kramer; Paul Dent; Steven Grant
Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(2):320-30.